ArticleMethods in molecular biology (Clifton, N.J.)2026
Carbohydrate Ligand-Mediated Precise Kidney Delivery of PNA.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivering drugs to the specific kidney cells remains a significant challenge in treating renal disorders. This chapter introduces a novel renal tubule targeting carbohydrate (RENTAC) ligand to precisely deliver peptide nucleic acid (PNA) to the proximal convoluted tubules of the kidney. We have reported the synthesis of the RENTAC ligand and a solution-phase PNA conjugation and characterization method. The methodology for elucidating the cellular uptake mechanism in cell culture and comprehensive biodistribution studies and evaluating the PNA-RENTAC conjugate efficacy in kidney fibrosis models is detailed. The reported methods are thoroughly validated and robust. This approach of ligand-mediated precise kidney delivery of PNA opens a vast platform for treating kidney disorders using antisense and antigene technologies.
Indexed as
Identifiers
42681102What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.